Lung Cancer
News
Pembro ups survival in NSCLC: ‘Really extraordinary’ results
The 3-year overall survival rate was 35% in the entire cohort and 99% in patients who completed all treatment cycles.
News
Glaring gap in CV event reporting in pivotal cancer trials
News
Walk test may predict complications after lung cancer surgery
Findings suggest role for curative resection in patients with moderately decreased lung function but a longer 6-minute walk distance,...
News
Lenvatinib/pembrolizumab has good activity in advanced RCC, other solid tumors
Two-thirds of patients with advanced renal cell carcinoma had a clinical response to the TKI/immune checkpoint inhibitor combination.
News
RCT confirms CT scan screening catches lung cancer early
CT screening of older people with heavy smoking histories – using lesion volume, not diameter, as a trigger for further work-up – reduced lung...
News
Sharp declines for lung cancer, melanoma deaths fuel record drop in cancer mortality
Reductions in smoking are largely responsible for the lung cancer progress, while immunotherapy and targeted treatments have improved survival in...
News
Large state disparities seen for lung cancer screening
Lung cancer screening for high-risk individuals remains low.
News
Not all lung cancer patients receive treatment
Reasons include metastasis and refusal, and rates by state vary from 8% to 30%, the American Lung Association reports.
Conference Coverage
Neoantigen vaccine appears safe and active in NSCLC
NATIONAL HARBOR, MD. – The vaccine produced only grade 1 adverse events and yielded responses in 7 of 24 patients,...
News
Lorlatinib induces deep responses in ROS1-positive NSCLC
Among 40 crizotinib-pretreated patients, 14 patients (35%) had an objective response on lorlatinib, with a median duration of response of 13.8...
